At a glance
ClinicalIndex Comparison RecordN/ACompleted· 9,571 enrolled
Drug / intervention
Empagliflozindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of T2DM Patients in Germany Receiving Empagliflozin: A Retrospective RWE Study Description of Treatment and Population Characteristics of Type 2 Diabetic Patients in Germany Receiving Empagliflozin: A Retrospective Real-World Evidence (RWE) Study Based on German Registries DPV&DIVE
In Brief
An observational study evaluating Empagliflozin for Diabetes Mellitus, Type 2. Completed, enrolled 9,571 participants across 1 site.
Detailed Summary
Description of the real-life treatment of adult patients with type-2 diabetes mellitus (T2DM) receiving Empagliflozin, comparing the characteristics of patients starting Empagliflozin in three time intervals
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartSep 2019
First PostedSep 2019
Primary CompletionDec 2019
TodayJul 2026
First PostedSep 23, 2019
Enrollment StartSep 16, 2019
Primary CompletionDec 31, 2019
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.8 years ago
Interventions
Empagliflozindrug
drug